News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of […] May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Apr 2023 6 new vaccines being developed for difficult-to-treat diseases There are several promising new vaccine candidates being developed for complex diseases that historically have been extremely difficult to find treatments and cures for. The development of these new vaccines could eventually lead to breakthrough treatments for diseases such as Alzheimer’s disease, HIV, Parkinson’s disease, Lyme disease, and breast cancer. According to the World Health […] April 12, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 Alzamend pushing ahead with Alzheimer’s vaccine trial Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose of the trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of Alzamend Neuro’s ALZN002 compared with that of placebo in […] April 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 €260M fund addresses dementia investment shortfall EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2023 5 advancements in Down syndrome research over the past year It was in 1959 when an extra chromosome on the 21st pair in the human cell was discovered by French geneticist Jerome Jean Louis Marie Lejeune. This was followed by research in the discipline of cytogenetics – the study of chromosomes. This chromosomal aberration which affects around one in 1000 live births worldwide, is called […] March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Could changing mRNA provide a new target for Alzheimer’s disease? Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model. This is according to a new study in the open access journal PLOS Biology by Rui Zhang of Air Force Medical University in Xian, Shaanxi, China. The results highlight […] March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 The challenges of tackling dementia in women Dr Andrea Pfeifer, chief executive officer of AC Immune SA, talks to Labiotech about dementia research, and how dementia affects women. She also addresses how vital research is when it comes to addressing women’s health. Dementia is a leading cause of death in women, but it doesn’t get the attention of other diseases, such as […] March 8, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline Sometimes, there’s an interview that we do that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer […] February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2023 EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease BioArctic AB’s partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab, known as LEQEMBI in the U.S., is an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed […] January 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […] January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Silo Pharma looks into the 2023 psychedelics crystal ball Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […] January 11, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email